MCID: RNV001
MIFTS: 49

Renovascular Hypertension

Categories: Cardiovascular diseases, Nephrological diseases

Aliases & Classifications for Renovascular Hypertension

MalaCards integrated aliases for Renovascular Hypertension:

Name: Renovascular Hypertension 12 6 15 17 33
Hypertension, Renovascular 44 72
Hypertension Renovascular 55

Classifications:



External Ids:

Disease Ontology 12 DOID:1591
MeSH 44 D006978
NCIt 50 C85044
ICD10 33 I15.0
UMLS 72 C0020545

Summaries for Renovascular Hypertension

MalaCards based summary : Renovascular Hypertension, also known as hypertension, renovascular, is related to malignant renovascular hypertension and nephrosclerosis. An important gene associated with Renovascular Hypertension is REN (Renin), and among its related pathways/superpathways are Calcium signaling pathway and Fluid shear stress and atherosclerosis. The drugs Aspirin and Amlodipine have been mentioned in the context of this disorder. Affiliated tissues include kidney, testes and heart, and related phenotypes are cardiovascular system and homeostasis/metabolism

Wikipedia : 75 Renovascular hypertension is a condition in which high blood pressure is caused by the kidneys' hormonal... more...

Related Diseases for Renovascular Hypertension

Diseases in the Renovascular Hypertension family:

Benign Renovascular Hypertension Malignant Renovascular Hypertension

Diseases related to Renovascular Hypertension via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 314)
# Related Disease Score Top Affiliating Genes
1 malignant renovascular hypertension 34.8 REN EDN1
2 nephrosclerosis 32.2 AGTR1 ACE
3 renal hypertension 31.3 REN EDN1 AGTR1 ADM ACE
4 fibromuscular dysplasia 31.3 REN AGTR1 ACE
5 renal artery obstruction 31.3 REN ACE
6 hypertensive retinopathy 31.2 REN ACE
7 hypertensive encephalopathy 31.2 REN ACE
8 hypertension, diastolic 30.9 REN ACE
9 renal tuberculosis 30.7 REN EDN1
10 arteriosclerosis 30.4 HMOX1 EDN1 ADM ACE
11 renal artery disease 30.2 REN NOS3 AGTR1 ACE
12 angina pectoris 30.1 NOS3 EDN1 ACE
13 limb ischemia 30.1 NOS3 EDN1 ACE
14 ischemia 30.1 NOS3 HMOX1 EDN1 ACE
15 hypertensive nephropathy 30.0 AGTR1 ACE
16 microvascular complications of diabetes 3 30.0 AGTR1 ACE
17 congenital hepatic fibrosis 29.9 REN AGTR1
18 aortic coarctation 29.9 NOS3 EDN1 AGTR1 ACE
19 cerebrovascular disease 29.7 REN AGTR1 ADM ACE
20 stroke, ischemic 29.5 REN NOS3 AGTR1 ACE
21 vascular disease 29.5 REN NOS3 HMOX1 EDN1 CAT ACE
22 conn's syndrome 29.5 REN NPPA AGTR1
23 hypertensive heart disease 29.4 AGTR1 ACE
24 pulmonary edema 29.4 REN NPPA NOS3 HMOX1 EDN1 ACE
25 sexual disorder 29.3 NOS3 NOS1 EDN1 ACE
26 acute myocardial infarction 29.1 NPPA EDN1 AGTR1 ACE
27 malignant hypertension 29.0 REN NPPA EDN1 AGTR1 ADM ACE
28 arteries, anomalies of 29.0 REN NOS3 EDN1 AGTR1 ACE
29 hypertension, essential 29.0 REN NPPA NOS3 EDN1 AGTR1 ADM
30 diabetes mellitus, noninsulin-dependent 29.0 NOS3 EDN1 AGTR1 ACE
31 congestive heart failure 28.7 REN NPPA EDN1 AGTR1 ADM ACE
32 diabetes mellitus 27.9 REN NOS3 EDN1 CAT AGTR1 ACE
33 kidney disease 27.8 REN NPPA NOS3 HMOX1 EDN1 AGTR1
34 pre-eclampsia 27.7 REN NPPA NOS3 HMOX1 EDN1 AGTR1
35 heart disease 27.7 REN NPPA NOS3 EDN1 AGTR1 ADM
36 myocardial infarction 27.5 REN NPPA NOS3 EDN1 AGTR1 ADM
37 benign renovascular hypertension 12.5
38 neurofibromatosis, type iv, of riccardi 10.7
39 takayasu arteritis 10.6
40 arteritic anterior ischemic optic neuropathy 10.6 NOS3 ACE
41 orthostatic proteinuria 10.5 REN ACE
42 malignant hypertensive renal disease 10.5 REN EDN1
43 malignant secondary hypertension 10.5 REN EDN1
44 perinephritis 10.5 REN EDN1
45 anterolateral myocardial infarction 10.5 NPPA ACE
46 malignant essential hypertension 10.5 REN ACE
47 acute kidney failure 10.5
48 hypokalemia 10.5
49 aortitis 10.5
50 pheochromocytoma 10.5

Graphical network of the top 20 diseases related to Renovascular Hypertension:



Diseases related to Renovascular Hypertension

Symptoms & Phenotypes for Renovascular Hypertension

MGI Mouse Phenotypes related to Renovascular Hypertension:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.19 ACE ADM AGTR1 EDN1 HMOX1 NF1
2 homeostasis/metabolism MP:0005376 10.14 ACE ADM AGTR1 CAT EDN1 HMOX1
3 behavior/neurological MP:0005386 10.11 ACE ADM AGTR1 HMOX1 NF1 NOS1
4 hematopoietic system MP:0005397 10.09 ACE ADM AGTR1 HMOX1 NF1 NOS1
5 growth/size/body region MP:0005378 10.06 ACE AGTR1 EDN1 HMOX1 NF1 NOS1
6 endocrine/exocrine gland MP:0005379 10.02 ACE ADM EDN1 HMOX1 NF1 NOS1
7 immune system MP:0005387 9.97 ACE ADM AGTR1 HMOX1 NF1 NOS1
8 mortality/aging MP:0010768 9.96 ACE ADM AGTR1 CAT EDN1 HMOX1
9 adipose tissue MP:0005375 9.92 ACE AGTR1 HMOX1 NOS1 NOS3
10 liver/biliary system MP:0005370 9.8 ACE ADM HMOX1 NF1 NOS1 NOS3
11 muscle MP:0005369 9.76 ADM EDN1 HMOX1 NF1 NOS1 NOS3
12 renal/urinary system MP:0005367 9.65 ACE ADM AGTR1 EDN1 HMOX1 NF1
13 reproductive system MP:0005389 9.1 ACE ADM HMOX1 NOS1 NOS3 REN

Drugs & Therapeutics for Renovascular Hypertension

Drugs for Renovascular Hypertension (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 48)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
2
Amlodipine Approved Phase 3 88150-42-9 2162
3
Angiotensin II Approved, Investigational Phase 3 11128-99-7, 68521-88-0, 4474-91-3 172198
4
Atorvastatin Approved Phase 3 134523-00-5 60823
5
Candesartan cilexetil Approved Phase 3 145040-37-5 2540
6
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
7
Candesartan Experimental Phase 3 139481-59-7 2541
8 Fibrinolytic Agents Phase 3
9 Cyclooxygenase Inhibitors Phase 3
10 Analgesics, Non-Narcotic Phase 3
11 Peripheral Nervous System Agents Phase 3
12 Analgesics Phase 3
13 Anti-Inflammatory Agents, Non-Steroidal Phase 3
14 Anti-Inflammatory Agents Phase 3
15 Antipyretics Phase 3
16 Platelet Aggregation Inhibitors Phase 3
17 Antirheumatic Agents Phase 3
18 Angiotensin Receptor Antagonists Phase 3
19 Antihypertensive Agents Phase 3
20 Anticholesteremic Agents Phase 3
21 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 3
22 Hormones Phase 3
23 Angiotensinogen Phase 3
24 Angiotensin II Type 1 Receptor Blockers Phase 3
25 Giapreza Phase 3
26 Amlodipine, atorvastatin drug combination Phase 3
27 Hypolipidemic Agents Phase 3
28 Lipid Regulating Agents Phase 3
29 Calcium, Dietary Phase 3
30 calcium channel blockers Phase 3
31 Antimetabolites Phase 3
32
Heparin Approved, Investigational 9005-49-6 46507594 772
33
Lidocaine Approved, Vet_approved 137-58-6 3676
34
Sunitinib Approved, Investigational 557795-19-4, 341031-54-7 5329102
35
Bevacizumab Approved, Investigational 216974-75-3
36
Cediranib Investigational 288383-20-0 9933475
37 Tezosentan Investigational 180384-57-0
38 Anesthetics, Local
39 Pharmaceutical Solutions
40 Anesthetics
41 calcium heparin
42 HIV Protease Inhibitors
43
protease inhibitors
44 Angiotensin-Converting Enzyme Inhibitors
45 Angiogenesis Inhibitors
46 Angiogenesis Modulating Agents
47 Protein Kinase Inhibitors
48 Antineoplastic Agents, Immunological

Interventional clinical trials:

(show all 18)
# Name Status NCT ID Phase Drugs
1 Phase 4 Study of Medical Therapy Versus Medical Therapy Plus Renal Artery Stenting in Preventing the Progression of Renal Failure in Atherosclerotic Renovascular Disease Unknown status NCT01023373 Phase 4 Medical treatment
2 Percutaneous Renal Stenting in Renovascular Disease With or Without Distal Atheroembolic Protection Unknown status NCT00868972 Phase 2, Phase 3
3 Effect of Aspirin on Renal Disease Progression in Patients With Type 2 Diabetes: a Multicentre Double-blind, Placebo-controlled, Randomised Trial. The LEDA (renaL disEase Progression by Aspirin in Diabetic pAtients) Study. Unknown status NCT02895113 Phase 3 Aspirin
4 Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL) Completed NCT00081731 Phase 3 Atacand/HCT, Caduet
5 A Phase 2a, Randomized, Placebo-controlled, Single Center Trial to Evaluate the Impact of Intravenous Bendavia™ (MTP-131) on Ischemia Reperfusion Injury in Atherosclerotic Renal Artery Stenosis in Patients Undergoing Percutaneous Transluminal Angioplasty of the Renal Artery (PTRA) Terminated NCT01755858 Phase 1, Phase 2 Bendavia;Placebo
6 Phase I Study of Autologous Mesenchymal Stem Cells in the Treatment of Atherosclerotic Renal Artery Stenosis Completed NCT01840540 Phase 1 Arterial infusion of autologous mesenchymal stem cells
7 Hypoxia and Inflammatory Injury in Human Renovascular Hypertension : Phase 1 Trial of Mesenchymal Stem Cell Therapy Active, not recruiting NCT02266394 Phase 1 Mesenchymal stem cell
8 Cardiovascular, Renal and Metabolic Profile in Patients With Acute Myocardial Infarction (AMI) Included in the Romanian National Programme of Primary Percutaneous Revascularisation - a Single Center Observational Study Unknown status NCT02388139
9 Renal Atherosclerotic Revascularization Evaluation: RAVE Study Completed NCT00127738
10 REFORM Clinical Study: Treatment of Renal Artery Stenosis With the Formula Balloon-Expandable Stent Completed NCT00631540
11 Assessment of Renal Artery Stenosis and Renovascular Hypertension by Contrast Enhanced Magnetic Resonance Imaging: A Pilot Study Completed NCT00006173
12 PROgression of FIbromuscular LEsions Completed NCT02961868
13 Assessment of Renal and Cervical Artery DysplasIA Completed NCT02884141
14 A Prospective Danish National Registry of Percutaneous Transluminal Renal Angioplasty in Patients With Renovascular Hypertension Recruiting NCT02770066
15 ARTISAN: iCAST™ RX De Novo Stent Placement for the Treatment of Atherosclerotic Renal Artery Stenosis in Patients With Resistant Hypertension Active, not recruiting NCT01673373
16 The Role of VEGF-A Signaling in Maintenance of the Glomerular Filtration Barrier and Blood Pressure Active, not recruiting NCT00691730
17 Kidney Transplantation and Renal and Myocardial Perfusion Active, not recruiting NCT02960802
18 A Multicenter Registry of Endovascular Therapy for Renal Artery Stenosis in China Not yet recruiting NCT03080519

Search NIH Clinical Center for Renovascular Hypertension

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Fenoldopam
Fenoldopam Mesylate

Cochrane evidence based reviews: hypertension, renovascular

Genetic Tests for Renovascular Hypertension

Anatomical Context for Renovascular Hypertension

MalaCards organs/tissues related to Renovascular Hypertension:

41
Kidney, Testes, Heart, Endothelial, Brain, Smooth Muscle, Cortex

Publications for Renovascular Hypertension

Articles related to Renovascular Hypertension:

(show top 50) (show all 4887)
# Title Authors PMID Year
1
Divergences in antihypertensive therapy in special situations in nephrology. 9 38
18425285 2008
2
Pre-operative renal function and selective renal vein renin levels as markers of favourable outcome in renovascular hypertension. 9 38
18062531 2007
3
Pre-operative renal function and selective renal vein renin levels as markers of favourable outcome in renovascular hypertension. 9 38
17489524 2007
4
Assessment of renal artery stenosis severity by pressure gradient measurements. 9 38
17084261 2006
5
Reversible renin-dependent renovascular hypertension successfully treated with percutaneous transluminal renal angioplasty and stenting. 9 38
15876819 2005
6
Renovascular hypertension. 9 38
15695858 2005
7
[Should renal vein catheterization for selective renin determination be performed in patients with suspected renovascular hypertension?]. 9 38
15515466 2004
8
Plasma adrenomedullin concentrations in patients with renovascular or malignant hypertension. 9 38
15284680 2004
9
Encapsulated transgene cells attenuate hypertension, cardiac hypertrophy and enhance renal function in Goldblatt hypertensive rats. 9 38
15241786 2004
10
Six missense mutations of the epithelial sodium channel beta and gamma subunits in Japanese hypertensives. 9 38
15198480 2004
11
Cyclooxygenase-2 up-regulation in reflux nephropathy. 9 38
14501677 2003
12
Phase-contrast magnetic resonance flow quantification in renal arteries: comparison with 133Xenon washout measurements. 9 38
12511539 2003
13
NT-proANP and BNP in renovascular and in severe and mild essential hypertension. 9 38
12697975 2003
14
Renal vein renin measurements accurately identify renovascular hypertension caused by total occlusion of the renal artery. 9 38
12011659 2002
15
On the significance of renal vein renins in renovascular hypertension. 9 38
12011641 2002
16
Hypertension and renovascular disease: follow-up on 100 renal vein renin samplings. 9 38
11967722 2002
17
Treatment options for renovascular hypertension. 9 38
11934344 2002
18
ACE inhibition is superior to angiotensin receptor blockade for renography in renal artery stenosis. 9 38
12002704 2002
19
Angiotensin I-converting enzyme gene polymorphism influences chronic hypertensive response in the rat Goldblatt model. 9 38
11875308 2002
20
The neurohormonal natural history of essential hypertension: towards primary or tertiary aldosteronism? 9 38
11791020 2002
21
Prostaglandin I(2)/E(2) ratios in unilateral renovascular hypertension of different severities. 9 38
11463755 2001
22
[Nephrourology and nuclear medicine today]. 9 38
11512405 2001
23
Adrenomedullin gene delivery attenuates renal damage and cardiac hypertrophy in Goldblatt hypertensive rats. 9 38
11352835 2001
24
[Converting enzyme inhibitors in the diagnosis of secondary arterial hypertension --focus on the captopril test]. 9 38
11301909 2000
25
Functional testing: renin studies. 9 38
11022895 2000
26
The pathophysiology of renin release in renovascular hypertension. 9 38
11022891 2000
27
Autoantibodies against the angiotensin receptor (AT1) in patients with hypertension. 9 38
10930193 2000
28
Specific direct radioimmunoassay of angiotensin II (AT II) in human plasma and the effect of angiotensin converting enzyme (ACE) inhibitor. 9 38
10604545 1999
29
ACE inhibition scintigraphy in the management of hypertension in children. 9 38
10452277 1999
30
Radionuclide renography: a personal approach. 9 38
10321824 1999
31
Short-term modulation of the renin-angiotensin system does not alter plasma adrenomedullin concentration in humans. 9 38
9886897 1998
32
[Current pharmaco-therapeutic strategies in the treatment of arterial hypertension]. 9 38
9813738 1998
33
[Nuclear nephrology]. 9 38
9494337 1997
34
Endothelin and active renin levels in essential hypertension and hypertension with renal artery stenosis before and after percutaneous transluminal renal angioplasty. 9 38
9488241 1997
35
Renovascular hypertension with low-to-normal plasma renin: clinical and angiographic features. 9 38
9486089 1997
36
Plasma endothelin-1 level in patients with renovascular hypertension - does the kidney with stenosis of the renal artery upregulate production of endthelin-1? 9 38
9233908 1997
37
Consensus report on ACE inhibitor renography for detecting renovascular hypertension. Radionuclides in Nephrourology Group. Consensus Group on ACEI Renography. 9 38
8917196 1996
38
Renal extraction of atrial natriuretic peptide in hypertensive patients with or without renal artery stenosis. 9 38
8641732 1996
39
[Comparison of captopril angioscintigraphy and the renin test in diagnosis of renovascular hypertension]. 9 38
8755852 1996
40
Acute blockage of the renin system and differential renal vein renin determinations in the diagnosis of renovascular hypertension. 9 38
8727869 1996
41
Renovascular hypertension in blacks. 9 38
8834702 1996
42
Reversible nephrotic syndrome due to high renin state in renovascular hypertension. 9 38
7731487 1995
43
Effect of chronic ACE inhibition on the diagnostic value of renography for renovascular hypertension: a preliminary report. 9 38
7753462 1995
44
Regulation of the structural remodelling of the myocardium: from hypertrophy to heart failure. 9 38
7713113 1994
45
[Renal ablation by transcatheter renal arterial embolization in the treatment of benign renal disease]. 9 38
9261190 1994
46
Response to the captopril test is dependent on baseline renin profile. 9 38
8021469 1994
47
Captopril-stimulated renal vein renin measurements in the diagnosis of atherosclerotic renovascular hypertension. 9 38
8136101 1994
48
Renin secretion and captopril stimulation in hypertensive renal transplant recipients. 9 38
8178382 1994
49
[Evaluation criteria for captopril-kidney function scintigraphy using 99mTc-MAG3]. 9 38
8295828 1993
50
Scintigraphic evaluation of renovascular hypertension. 9 38
8128734 1993

Variations for Renovascular Hypertension

ClinVar genetic disease variations for Renovascular Hypertension:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 PKD1 NM_001009944.3(PKD1): c.9185T> A (p.Val3062Asp) single nucleotide variant Likely pathogenic rs1057518856 16:2152398-2152398 16:2102397-2102397

Expression for Renovascular Hypertension

Search GEO for disease gene expression data for Renovascular Hypertension.

Pathways for Renovascular Hypertension

GO Terms for Renovascular Hypertension

Cellular components related to Renovascular Hypertension according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.17 REN NPPA HMOX1 EDN1 CAT ADM
2 vesicle membrane GO:0012506 9.16 NOS3 NOS1
3 caveola GO:0005901 9.13 NOS3 NOS1 HMOX1

Biological processes related to Renovascular Hypertension according to GeneCards Suite gene sharing:

(show all 41)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.92 NOS3 NF1 HMOX1 ADM
2 heart development GO:0007507 9.86 NF1 EDN1 ADM
3 positive regulation of cytosolic calcium ion concentration GO:0007204 9.82 EDN1 AGTR1 ADM
4 positive regulation of angiogenesis GO:0045766 9.81 NOS3 HMOX1 ADM
5 kidney development GO:0001822 9.71 REN CAT AGTR1 ACE
6 response to insulin GO:0032868 9.7 NPPA CAT ADM
7 response to nicotine GO:0035094 9.68 HMOX1 EDN1
8 regulation of cardiac conduction GO:1903779 9.68 NPPA NOS1
9 regulation of angiogenesis GO:0045765 9.68 NF1 HMOX1
10 negative regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902042 9.67 NOS3 HMOX1
11 phosphatidylinositol 3-kinase signaling GO:0014065 9.67 NF1 EDN1
12 blood vessel remodeling GO:0001974 9.67 NOS3 ACE
13 positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G protein-coupled signaling pathway GO:0051482 9.66 EDN1 AGTR1
14 negative regulation of blood pressure GO:0045776 9.66 NOS3 NOS1
15 positive regulation of blood vessel diameter GO:0097755 9.65 HMOX1 ADM
16 positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903589 9.65 HMOX1 AGTR1
17 vasodilation GO:0042311 9.64 NOS3 NOS1
18 regulation of sodium ion transport GO:0002028 9.63 NOS3 NOS1
19 nitric oxide mediated signal transduction GO:0007263 9.63 NOS3 NOS1
20 response to muscle stretch GO:0035994 9.62 NPPA EDN1
21 regulation of blood vessel diameter GO:0097746 9.61 AGTR1 ACE
22 negative regulation of calcium ion transport GO:0051926 9.61 NOS3 NOS1
23 amyloid-beta metabolic process GO:0050435 9.6 REN ACE
24 nitric oxide biosynthetic process GO:0006809 9.59 NOS3 NOS1
25 angiotensin maturation GO:0002003 9.58 REN ACE
26 positive regulation of guanylate cyclase activity GO:0031284 9.58 NOS3 NOS1
27 negative regulation of potassium ion transport GO:0043267 9.57 NOS3 NOS1
28 regulation of calcium ion transmembrane transport via high voltage-gated calcium channel GO:1902514 9.56 NPPA NOS1
29 negative regulation of hydrolase activity GO:0051346 9.55 NOS3 NOS1
30 response to lipopolysaccharide GO:0032496 9.55 REN NOS3 NOS1 EDN1 ADM
31 arginine catabolic process GO:0006527 9.54 NOS3 NOS1
32 regulation of vasoconstriction GO:0019229 9.54 EDN1 AGTR1 ACE
33 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.51 AGTR1 ACE
34 positive regulation of heart rate GO:0010460 9.5 NPPA EDN1 ADM
35 response to hypoxia GO:0001666 9.5 NPPA NOS1 NF1 HMOX1 EDN1 CAT
36 regulation of systemic arterial blood pressure by endothelin GO:0003100 9.49 NOS3 EDN1
37 response to ozone GO:0010193 9.48 EDN1 CAT
38 renin-angiotensin regulation of aldosterone production GO:0002018 9.46 REN AGTR1
39 smooth muscle hyperplasia GO:0014806 9.43 NOS3 HMOX1
40 regulation of blood vessel size GO:0050880 9.43 NPPA NOS3 EDN1
41 regulation of blood pressure GO:0008217 9.1 REN NPPA NOS3 HMOX1 EDN1 ACE

Molecular functions related to Renovascular Hypertension according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.81 NOS3 NOS1 HMOX1 CAT
2 hormone activity GO:0005179 9.65 NPPA EDN1 ADM
3 signaling receptor binding GO:0005102 9.55 REN NPPA EDN1 CAT ADM
4 FMN binding GO:0010181 9.49 NOS3 NOS1
5 arginine binding GO:0034618 9.46 NOS3 NOS1
6 NADPH-hemoprotein reductase activity GO:0003958 9.43 NOS3 NOS1
7 NADP binding GO:0050661 9.43 NOS3 NOS1 CAT
8 cadmium ion binding GO:0046870 9.4 NOS3 NOS1
9 tetrahydrobiopterin binding GO:0034617 9.37 NOS3 NOS1
10 nitric-oxide synthase activity GO:0004517 9.32 NOS3 NOS1
11 bradykinin receptor binding GO:0031711 8.96 AGTR1 ACE
12 heme binding GO:0020037 8.92 NOS3 NOS1 HMOX1 CAT

Sources for Renovascular Hypertension

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....